12:30 PM – 1:00 Lunch and Registration
1:00 PM – 1:15 PM Welcome and Introduction
1:15 PM – 1:45 PM Diagnosis and Risk Stratification of Plasma Cell Disorders: To Treat or Not to Treat
1:45 PM – 2:15 PM Evolution of Upfront Therapy for the ASCT-Ineligible Patient
2:15 PM – 2:45 PM Upfront Therapy for the ASCT-Eligible Patient: Advances in Induction, ASCT, Consolidation, and Maintenance Therapy
2:45 PM – 3:15 PM The Current Therapeutic Landscape for Relapsed or Refractory MM: Which Combinations to Use and When?
3:15 PM – 3:45 PM Future Directions: A New Era of Promising Treatments for MM
3:45 PM – 4:00 PM 2020 Treatment Algorithm for MM and Conclusions
Date / Time
Hyatt Regency Orlando
Brian G.M. Durie, MD
Medical Director, AMyC
Co-Chair Myeloma Committee, SWOG
Chairman, International Myeloma Foundation
Specialist in Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California
Shaji Kumar, MD
Department of Hematology
Thomas G. Martin, MD
Clinical Professor of Medicine
Associate Director, Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California
Philippe Moreau, MD
Professor of Clinical Hematology
Head, Hematology Department
University Hospital Hôtel-Dieu
S. Vincent Rajkumar, MD
Edward W. and Betty Knight Scripps
Professor of Medicine
Jesus San-Miguel, MD
Director of Clinical and Translational Medicine
Universidad de Navarra
The goal of this activity is to improve participants’ competence in and performance at applying practice-changing clinical data and expert recommendations to optimize the care of their patients with multiple myeloma.
This program is intended for physicians and other healthcare providers who care for patients with multiple myeloma.
- Initiate treatment for appropriate patients based on an accurate diagnosis of monoclonal gammopathy of undetermined significance, smoldering MM, or active MM
- Create individualized treatment strategies for patients with newly diagnosed MM through consideration of the available clinical data as well as risk assessment, age, comorbidities, and patient preferences
- Select safe and effective maintenance therapy for patients with MM based on risk and response to induction therapy
- Evaluate the efficacy and safety of combination regimens to individualize therapeutic strategies for patients with MM at first relapse
- Plan appropriate treatment strategies using all available agents and classes to provide efficacious combination therapies to heavily pretreated patients with relapsed/refractory MM
- Employ novel agents and clinical trial participation as part of clinical care strategies for MM
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Clinical Care Options, LLC. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
All faculty, staff, and reviewers involved in the planning, review, or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.